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Leading in education, therapeutic
approaches, and innovative research

A message from the Chief
Leading in education, therapeutic
approaches, and innovative research
The UNMC Division of Rheumatology is recognized both nationally and internationally as a
leader in innovative treatments for rheumatoid arthritis, for outcomes and database research
and for treatments of gout. Further, the division has an unparalleled record of educating
fellows, residents and students on the rheumatic diseases. Our mission is to continue pursuing
ground breaking approaches in research, clinical care and education in rheumatic diseases.

James R. O’Dell, MD

UNMC researchers have made major contributions to rheumatology through the conduct of
investigator-initiated clinical trials in The Rheumatology and Arthritis Investigational Network
(RAIN) over the past two decades. RAIN is recognized internationally as the largest network of its
kind in the United States that specializes in RA investigator-initiated clinical research. The RAIN
network was responsible for multiple innovative studies including the initial trial and subsequent
worldwide prominence of “Triple Therapy” in the management of rheumatoid arthritis (NEJM 1996).
The Nebraska Arthritis Outcomes Research Center (NAORC) was established in
2007 by the generous donation by Ruth and Bill Scott and represents a collaborative
effort of our division with the UNMC Department of Orthopaedics.
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Researchers from the Division of Rheumatology, in efforts both at UNMC and the Omaha VA Medical
Center, actively collaborate on a national and international level to address important clinical questions:
1. NAORC researchers recently conducted the largest study ever demonstrating an
association between gum disease and the risk of developing rheumatoid arthritis. The
results suggest that treatments aimed at gum disease could play an important role
in arthritis treatment and prevention. This study involved investigators at UNMC and
VA medical centers in Omaha, Dallas, Washington and Salt Lake City. This work has
led to collaborations with investigators from across the U.S. and in Europe.
2. The multicenter, multi-national Rheumatoid Arthritis Comparison of Active Therapies (RACAT)
study was led by our division at the Omaha VA and UNMC and included NAORC investigators.
The study, published as the lead article in the July 25, 2013 issue of the New England Journal
of Medicine, demonstrated clearly that a combination of conventional generic medications
(Triple Therapy) works as well as newer, more expensive biologic medicines in the treatment of
rheumatoid arthritis. Thus, providing the potential of huge cost savings without sacrificing quality.
3. Another national program directed by our division is the Veteran Affairs Rheumatoid
Arthritis (VARA) registry created more than 10 years ago. This registry is the largest
and best characterized, predominantly male RA cohort in the world. VARA, in addition
to Omaha, now includes enrollment sites at 11 VA medical centers across the country
including those located in Birmingham, Brooklyn, Dallas, Denver, Iowa City, Jackson,
Little Rock, Portland, Philadelphia, Salt Lake City and Washington, D.C.
We strive to provide exceptional comprehensive clinical care. For example, UNMC is a leader in
musculoskeletal ultrasound. This valuable tool provides physicians with better information about the
conditions they treat. Future rheumatologists are educated through the fellowship program in the
Division of Rheumatology. Our fellows have a perfect 100 percent pass rate on rheumatology boards
for the entire history of our program. Our residents and fellows frequently have the opportunity to
participate in research and present at the annual American College of Rheumatology conference.
Current advances in rheumatology and exciting and promising avenues make rheumatology
a vibrant and growing one. UNMC’s Division of Rheumatology is proud to have the
people, programs and cutting-edge research projects to participate in these advances,
helping position the division to support our patients and those around the world.
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From left, Alan Erickson, MD, Amy Cannella, MD, MS, Gerald Moore, MD, James O’Dell, MD,
Lynell Klassen, MD, Ted Mikuls, MD, MSPH, and Michelene Hearth-Holmes, MD, MEd

The Division of Rheumatology is a national and international leader in
the diagnosis and treatment of diseases that affect the joints, connective
tissue diseases, and autoimmune diseases. We are pursuing state-ofthe-art approaches in research, clinical care, and education programs
in rheumatic diseases, with areas of expertise to include rheumatoid
arthritis, osteoarthritis, granulomatosis with polyangiitis, gout and
systemic lupus erythematosus. Private donations have led to the founding
of the Nebraska Arthritis Outcomes Research Center (NAORC), have
directly supported the world renowned Rheumatology and Arthritis
Investigational Network (RAIN), and have allowed us to lead research
efforts devoted to improving the quality of life for our patients.

19 Faculty Publications &
Research Awards
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Nebraska Arthritis Outcomes Research
Center puts UNMC on cutting edge
links between investigators across our campus
and across the U.S., all with the common goal of
improving outcomes for our arthritis patients,”
said Dr. Mikuls. “Our collaborations have led
to important work in several areas and now
includes active and highly productive work
with investigators from the Colleges of Public
Health, Pharmacy, and Dentistry among others.”
Since its inception in 2007, NAORC has
made substantial progress in research
focused on gaining a better understanding
of arthritis risk, its impact on patients and
the best treatment strategies. In addition to
leading cutting edge research programs and
supported in large part by initial NAORC
funding, center faculty members have:
• expanded the center’s reach both
nationally and internationally;
• grown the research infrastructure
at UNMC and the Omaha VA for
arthritis-focused investigations;
• trained the next generation of
arthritis researchers; and

The Nebraska Arthritis Outcomes Research Center made
possible by a major donation by Bill and Ruth Scott

• developed a strong publication portfolio.

Center’s Opening a
great milestone for
research, education
at UNMC

In July 2007, the Nebraska Arthritis Outcomes
Research Center (NAORC), a collaborative
effort of the Division of Rheumatology and
the Department of Orthopaedics, was
established on the UNMC campus.
The center, under the direction of Ted
Mikuls, MD, MSPH, and Kaleb Michaud,
PhD, conducts studies to better understand
the development of arthritis and predict
outcomes. The center was made possible by
a major donation by Ruth and Bill Scott.
The opening of NAORC was a great milestone
for research and education in the Rheumatology
Division. NAORC brings together advanced
research in rheumatology and orthopaedics, with
the support and integration of large relational
databases, clinical registries and biorepositories,
information technology, and statistical support.
Scientists from UNMC are increasingly well
positioned to investigate arthritis and disease
epidemiology in arthritis. Together, the
Department of Orthopaedics and the Division
of Rheumatology account for thousands of
outpatient visits annually at UNMC, providing
referral services to a five state area in the
Midwest. “NAORC has facilitated important
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NAORC’s goals over the next five years are to
continue to expand these efforts with targeted,
strategic faculty recruitments and expansion
of currently available infrastructure supporting
clinical and translational arthritis research.

NAORC ACCOMPLISHMENTS
SINCE 20 07 INCLUDE:

Cutting Edge Research
• The Treatment of Rheumatoid Arthritis
The multicenter, multinational RACAT study
was led by Omaha VA and UNMC NAORC
investigators. Recently published in the New
England Journal of Medicine (July 2013) and
receiving national media attention, the study
showed that a combination of conventional
generic medications works as well as
newer, more expensive biologic medicines
in the treatment of rheumatoid arthritis.
• Novel Methods of Drug Delivery in Arthritis
NAORC research efforts have led to highly
innovative strategies of selectively delivering
arthritis treatments to the inflamed joint.
By targeting (and limiting) drug delivery
to the diseased joint, these new treatment
approaches hold substantial promise in
limiting common drug-related toxicities that
complicate arthritis management. Pilot studies

examining the use of these novel drug delivery
systems in treating joint replacement failure
(loosening of implants) has been funded
directly with NAORC-provided funding.
• The Benefits and Safety of Total Joint
Replacement NAORC research efforts have
demonstrated for the first time using metaanalysis that shoulder replacement surgery
leads to substantial improvement in overall
quality of life for patients suffering from endstage shoulder arthritis. More recent efforts
have focused on finding new ways of detecting
infections impacting joint replacements and
examining the impact and risk of procedures
among those with rheumatoid arthritis.
• Links Between Oral Health and Arthritis
NAORC researchers recently conducted the
largest study ever completed demonstrating
an association between gum disease with
the risk of developing rheumatoid arthritis.
The results suggest that treatments aimed
at gum disease could play an important
role in arthritis treatment and prevention.
• Novel Methods of Treating Gout As
part of a NIH-funded program project
grant, NAORC researchers are examining
new ways of delivering gout care with
the goal of improving outcomes in an
often poorly managed condition.
• New Animal Models of Arthritis NAORC
research efforts have for the first time led to
the development of a new animal model for
rheumatoid arthritis, one that more closely
mimics human disease and that will be vital in
examining new treatment paradigms in disease.

of California San Francisco, and Harvard
to name a few) in addition to arthritis
research centers in Europe (Kennedy
Institute in the U.K., the Karolinska
Institute in Stockholm and others).

Building Support for State-ofthe-Art Arthritis Research
• Registries and Biobanks NAORC leads the
nation in the development of biorepositories
and linked patient registries. These
resources are vital in translating scientific
discoveries into the arthritis clinic and serve
as a research resource not only for UNMC
investigators, but also for investigators both
nationally and internationally. Efforts include
the National Data Bank for Rheumatic
Diseases (NDB), the VA Rheumatoid Arthritis
Registry (VARA), the Rheumatology and
Arthritis Investigational Network (RAIN)
Database and, most recently, the Arthritis
Internet Registry (AIR). NDB, RAIN, and
AIR efforts have been led by Dr. Michaud
with funding support from NAORC. NAORC
support has allowed Dr. Michaud to develop
and maintain links between registries
and electronic health record data.
• FOCIS Center of Excellence Based on
efforts to date, UNMC’s NAORC was
designated a Federation of Clinical
Immunology Societies (FOCIS) Center
of Excellence. UNMC is one of only 62
centers nationally with this recognition.

• State-of-the-Art Imaging in Arthritis
NAORC researchers have developed
and refined novel methods for precisely
characterizing joint damage resulting as
a consequence of arthritis. These efforts
include the acquisition of state-of-the-art
micro-CT scans (using predominantly NAORC
funds) to characterize disease models
in addition to the dynamic ultrasound in
arthritis patients, a noninvasive approach
that can be used in diagnosis and to
guide therapeutic joint injections.
• Lupus Clinic Led by Dr. Michelene HearthHolmes, NAORC faculty have established
the new state-of-the-art Lupus Clinic in
the Division of Rheumatology, a clinic
that will serve as a vital resource for
lupus researchers at UNMC. With this
clinic as the foundation, UNMC now
has a NIH-funded research portfolio
in lupus and is participating in studies
examining lupus treatments.
• Examining the Impact of Arthritis and
its Treatment in U.S. Veterans NAORC
has led efforts to expand clinical research
programs to the Omaha VA, spearheading
two large national cooperative studies
examining arthritis treatment. Additional
ongoing VA research includes the national
VA Rheumatoid Arthritis Registry (VARA)
and more recent efforts focused on
improving the quality of gout care.

Attracting the Best and
Brightest Researchers at
UNMC and Elsewhere
• Collaborations of center researchers have
expanded across the University of Nebraska
system and now include: Dong Wang, PhD
(UNMC College of Pharmacy); Kaihong Su,
PhD (UNMC Department of Pathology); Jason
(Zhixin) Zhang, PhD (UNMC Department of
Pathology); Fang Yu, PhD (UNMC College
of Public Health); and Jeffrey Payne, DDS
(UNMC College of Dentistry), among others.
• National and international collaborations
now include researchers at top-tier
institutions in the U.S. (Stanford University,
Johns Hopkins, Mayo Clinic, University

From left to right, Ted Mikuls, MD,
MSPH, and Kaleb Michaud, PhD
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Medical education:
A fresh perspective
Amy Cannella, MD, MS, sees exciting new
educational opportunities for students and fellows.

“We can diagnose,
treat, and educate
patients in real time,
at the clinic visit”
Amy Cannella,
MD, MS

Dr. Cannella, fellowship director for the UNMC Division of Rheumatology, and her colleagues, are
sharing that excitement, as well as dedication to their chosen field, with each group of internal
medicine students, residents and fellows.
Dr. Cannella described three major educational efforts in the division:
• The fellowship program with a 100 percent board pass rate;
• Education of the internal medicine residents;
• Medical student education (M2 and M3).
The division has two incoming fellows per year to complete a two-year fellowship at UNMC (with an
option for a third year of research).
“These are very educationally oriented fellowships,” she said. “We have a lot of didactic teaching and
a pretty intense curriculum that includes clinical rheumatology, musculoskeletal ultrasound and bone
health.”
Fellows attend the American College of Rheumatology’s annual meeting, senior fellows go to the “stateof-the-art” meeting, and senior fellows also participate in a national ultrasound curriculum—a new
initiative that is part of the changing world of rheumatological education.
“Ultrasound has been increasingly picked up by many specialties,” Dr. Cannella said. “It shows us what
the tissues look like under the skin. We can see if there’s pathology, and it can direct treatment. We can
diagnose, treat, and educate patients in real time at the clinic visit.”
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From left to right: Amy Cannella, MD, MS, Rheumatology Fellowship Program Director, Brian
Fay, MD, former fellow, Michelene Hearth-Holmes, MD, Jaclyn Anderson, DO, former
fellow and Michael Feely, MD, former fellow Center front: Alan Erickson, MD

Musculoskeletal ultrasound also provides physicians with better information about the conditions they
are seeking to treat.
“It’s good for patients to understand the pathophysiology of the disease,” Cannella said.
“Rheumatologists are making decisions in real time about what’s going on in terms of the joint or the
tissue. Patients love it.”
The rheumatology internal medicine resident training curriculum includes regular inpatient and
outpatient teaching rounds, a distinct pre- and post-test evaluation, a computer-based x-ray and
photographic case series and a didactic lecture series. Third year medical students may choose a
rheumatology elective during their internal medicine clerkship, an opportunity not always available in
other subspecialities.
“Residents and students also attend our didactic teaching sessions for the fellows,” Dr. Cannella said.
For the M2 musculoskeletal core, the division currently is redesigning the curriculum.

“Students have
changed, and have
different learning
needs and styles”
Amy Cannella,
MD, MS

“We’re trying to flip the classroom,” she said. Efforts include a video game to teach about gout, live
patients for medical students to interact with, more interactive, case-based activities and videotaped
lectures students can watch on their own time.
“Students have changed, and have different learning needs and styles then when I was in the classroom,”
Dr. Cannella said. “They don’t like to sit in lecture for hours—they want to do some things on their own
and then come in and have the discussion.”
“Rethinking medical education can be hard for some of us because medicine honors tradition. Ultimately,
we want to be sensitive to our learners’ needs, while instilling the same work ethic, humility and passion
for medicine that was passed down to us.”

From left to right: Anna Gramling, MD,
Zachary Pruhs, MD, Amy Cannella, MD, MS,
Leann Maska, MD, and Annika Cutinha, MD
(former fellows)
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The reader
Alan Erickson, MD,
serves as an “expert
reader” of films
for the Division of
Rheumatology.
Alan Erickson, MD, scoring x-rays

Dr. Erickson joined the UNMC Division
of Rheumatology in 2007 as a clinical
rheumatologist, which remains
the focus of his work today.

know—Do they have evidence of joint damage?
Do they have joint erosions and joint narrowing?”
As an expert reader of the radiographs,
Dr. Erickson looks specifically for bony
erosions and narrowing using a protocol
that’s called the Modified Sharp Scoring
Method—named after the physician mentor
who taught the technique to Dr. Erickson.

Thanks to James O’Dell, MD, who recognized
Dr. Erickson’s deep interest in radiography,
and the late John Sharp, MD, who mentored
Dr. Erickson in the techniques of reading
and scoring x-rays. Today he has rapidly
become recognized as an “expert reader,” an
essential part of such research efforts as the
Rheumatoid Arthritis Comparison of Active
Therapies (RACAT) trial and other studies like
it, examining the effects of rheumatoid arthritis
(RA) treatments. Along with Dr. Tim Moore
from the UNMC Department of Radiology, Dr.
Erickson read and scored films from the RACAT
study, results that were published in the New
England Journal of Medicine in July of 2013.

“It’s a well-established radiographic assessment
tool used in rheumatology to assess x-rays,”
Dr. Erickson said. “I was fortunate enough
to be taught the method by Dr. Sharp
after he visited us at UNMC in 2007.”

In addition to reading films from the RACAT
study and other national RA investigations,
Dr. Erickson is reading films for the Veterans
Affairs Rheumatoid Arthritis (VARA) registry, a
large national cohort of U.S. veterans with RA.

“Most importantly, it’s about consistency. When
readers look at x-rays, not everybody sees
an erosion, not everybody sees narrowing—
there’s a degree of subjectivity to this.”

“In a registry like the VARA registry, a lot of
time we’re just looking at x-rays for one point in
time,” Dr. Erickson said. “When we are trying
to assess the severity of individual patients’
inflammatory arthritis, like RA, we want to
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Dr. Erickson spent several days working
with Dr. Sharp to learn the basics. Dr. Sharp
subsequently sent Dr. Erickson batches of x-rays
to examine and score himself, so the two men
could compare their notes and conclusions.

But consistency is paramount.
“Do you always call erosion erosion? Do you
always call narrowing narrowing?” Dr. Erickson
asked. “When I’m looking at an x-ray, and

then I’m looking at an x-ray taken 24 weeks
later, we want to see if there are changes in
the radiographs. It’s important that a change
in the radiographs over time reflects a true
change over time, not a variability based on
whether or not I had a good night’s sleep.”
More recently, Dr. Erickson has assisted in
research efforts including a study examining
the relationship between severe gingivitis and
RA led by Ted Mikuls, MD, MSPH, at UNMC.
As part of this study, the team found that the
presence of periodontitis (a severe form of
gum disease) was associated with more x-ray
damage among RA patients, findings that were
recently published in Arthritis & Rheumatology.
‘’I act as a resource for Dr. Mikuls, Dr.
Michaud, and Dr. O’Dell in their research
trials,” Dr. Erickson said. “I fulfill a function
that is necessary so that these registries can
function the way they need to function, and the
research trials can do what they need to do.”
Dr. Erickson is proud to be assisting in the
Division of Rheumatology’s cutting edge research.
“These are important trials that are
definitely affecting how we look at and
treat rheumatoid arthritis,” he said. “It’s
exciting to be a part of that.”

Lupus study becomes international affair
Dr. Michelene Hearth-Holmes launches international lupus research study site.
Michelene Hearth-Holmes, MD, MEd from
the Division of Rheumatology has made
substantial strides in developing UNMC’s
growing presence in research focused on
systemic lupus erythematosus (SLE). She
currently shares a close collaboration with
Kaihong Su, PhD, Department of Pathology and
Microbiology, on Dr. Su’s NIH-funded grant
work examining novel biomarkers in SLE.
Dr. Hearth-Holmes’ role has been to act as the
clinical conduit for this groundbreaking research,
obtaining regulatory approvals, identifying a
cohort of lupus patients from the UNMC Lupus
Clinic that she directs, and tracking patients’
clinical data over the five-year study duration.
Study participants are seen annually and when
they have disease flares. Autoantibody tests are
then administered by Dr. Su and her laboratory
personnel to measure a novel biomarker
she discovered called anti-NOD27 antibody.
Circulating levels of this novel biomarker were
found to be significantly elevated in patients
with SLE compared to healthy control volunteers
based on preliminary results from the study.
Dr. Hearth-Holmes said a very interesting
aspect of the study, which occurred

fortuitously, was a connection made with
a clinician in the Dominican Republic, Dr.
Esthela Loyo, at the Hospital Regional
Universitario Jose Maria Cabral y Baez.
Dr. Loyo’s son, who was doing a sub-internship
at Creighton University, heard Dr. Su give a
talk there. After the lecture, he told Dr. Su
that his mother had many patients with
lupus in the Dominican Republic where she
practiced, and that he would speak to her
about Dr. Su’s research. Collaborations took off
from there. It turned out that Dr. Loyo follows
about 300 patients with lupus, all Hispanic.
Although there are lupus patients all over the
world, Dr. Hearth-Holmes said she did not
realize there were so many from a single clinic
alone in the Dominican Republic. Because
they are all Hispanic, unique from most
U.S. disease cohorts, this opens the doors
for exploring even more questions focused
on ethnic differences in disease expression.
Consent forms and questionnaires have been
translated into Spanish specifically for use in
the Dominican Republic with patients enrolled
in the UNMC-sponsored Rheumatology and

Arthritis Investigational Network (RAIN)
database. This database serves as a research
resource to examine determinants of arthritis
outcomes among patients with a variety of
diagnoses. This will substantially expand the
demographics of the RAIN database, which
was developed almost 10 years ago and is now
widely used among rheumatology researchers
nationally and internationally. With extensions
into the area of SLE and into the Dominican
Republic and beyond, RAIN researchers continue
to make progress in gaining important insights
into arthritis and other autoimmune conditions.
Dr. Hearth-Holmes’ cross-continental work
in support of SLE research is an important
part of that progress. The collaboration
with Dr. Loyo is just one example of how
UNMC’s Division of Rheumatology is reaching
across borders to research and battle
lupus and other autoimmune diseases.

From left to right, Michelene HearthHolmes, MD, MEd, and Kaihong
Su, PhD, assessing patient
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The puzzle of
‘the loss of self-tolerance’
Lynell Klassen, MD, has spent a career
grappling with one question: Why
do people react to their own tissue?
“ That’s a funny word—an immunological word—but what it really means is,
why do people start reacting to their own tissues?” he says.
Sitting at a table in his office on the UNMC campus, he talks about his
career: The early work at the National Institutes of Health, in what he
calls “the dark ages” of the 1970s; the development of the Experimental
Immunology Laboratory (EIL), currently being directed by his colleague,
Geoffrey Thiele, PhD; and later, the studies of alcoholic liver disease he
hoped would shed insight into environmental factors—specifically alcohol—
and how they affect autoimmune responses.
“People ask me, ‘What were you doing studying alcoholic liver disease as a
rheumatologist who did bone marrow transplants?’” he says with a laugh.
“There were opportunities at each institution I’ve been at, to use different
model systems to look at this question—how do you lose self-tolerance or
develop autoimmune disease?”
A rheumatologist, Dr. Klassen joined UNMC in 1982 and served as Vice
Chair of Medicine and Chief of Rheumatology at UNMC, where he initiated
the EIL, co-directed UNMC’s Bone Marrow Transplant Program and founded
the HIV clinic. He served on the National Institutes of Health National
Institute on Alcohol Abuse and Alcohol National Advisory Council. He also
held key posts with the American College of Rheumatology and American
College of Physicians (ACP).
Among his many awards, Dr. Klassen was inducted as a master of the
ACP in 2011. In the 98-year history of the ACP, only a handful of other
Nebraska physicians have received the master designation, which is given to
physicians exhibiting preeminence in practice or medical research, holding
positions of high honor or making significant contributions to medical
science or the art of medicine.
Currently, Dr. Klassen serves as Internal Medicine Chairman at UNMC and
sees rheumatology patients in clinic one to two days a week.
But he still has time to wrestle with the research subject that has fascinated
him since the beginning of his career. The classic disease example of loss
of self-tolerance, he says, is systemic lupus erythematosus—the body reacts
against itself destroying its own organ tissues. The question is, why does this
happen to some people and not others?
Over the years, Dr. Klassen and his colleagues have studied a variety
of different models to answer that question—a lupus animal model;
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Lynell Klassen, MD, and Geoffrey Thiele, PhD

examination of graft vs. host disease (GVHD), a consequence of bone
marrow transplant; and studying the environmental effect of alcohol in
causing the loss of self-tolerance.
From 2000-2010, his work earned him an NIH MERIT (Method to Extend
Research in Time) Award for innovative studies in the role of immune
responses in alcohol-associated tissue damage. He is one of only three
UNMC researchers to ever receive the prestigious MERIT Award.
He continues to grapple with the puzzle of self-tolerance.
“There are several exciting things happening now,” he says. “First, it appears
that there are certain patterns of antibody responses to the cell proteins
that clearly differentiate people at risk for heart attacks, and heart disease.
It appears that there are other antibody profiles that predispose people, or
predict people who are going to get rheumatoid arthritis.
“So why do you have this same reaction to a certain protein or piece of
process; why does it look different in this disease process vs. that disease
process?”
“There’s certainly a genetic base for that, and there’s certainly an
environmental base for that,” he said. “So we’re trying to figure out where all
of those things fit together.”
It’s a puzzle that’s lasted a professional lifetime—but Dr. Klassen is nowhere
near ready to give up.

An icon in rheumatology
Gerald Moore, MD, (far right) with students

A superlative internist, Dr. Gerald Moore’s biggest impact
may be his legacy of committed and talented students.
Ask one former student about Gerald Moore, MD,
and she’ll rattle off a rhyme.
“Small joint symmetrical synovitus means
rheumatoid arthritis.”
“I can remember my lectures with him as a
medical student,” said Amy Cannella, MD, MPH,
now a colleague of Dr. Moore’s at UNMC. “Every
time I see a patient with rheumatoid arthritis, I
hear him in my head.”
From 1974, when he was the chief resident and
an instructor at UNMC’s Department of Internal
Medicine, to today, Dr. Moore has had an impact
on medical education at UNMC. Today, Dr.
Moore serves as the Senior Associate Dean for
Academic Affairs for the College of Medicine and
Professor in the Division of Rheumatology in the
Department of Internal Medicine.
As Senior Associate Dean, he oversees the
College of Medicine admissions process,
educational program for students and residents
as well as faculty development issues. He has
been an administrator in the College of Medicine
for over 20 years, but continues to see patients in
both Rheumatology Clinic as well as patients on
the general internal medicine inpatient service.

“He’s an icon in rheumatology,” Dr. Cannella said.
“He’s an icon in medical education. He’s given
his entire life to education. He brings a lot of
enthusiasm, he is very practical in his approach
to patient care, and he’s a wonderful teacher.”
A native of Lincoln, Dr. Moore graduated from
Nebraska Wesleyan University in 1967 before
advancing to UNMC, where he earned his MD
in 1971. He has received more than $1 million in
grant and contract funding for studies on medical
education, but his interest in education is not
simply academic. A long string of awards for
his exemplary teaching skills include the LeeRoy
Meyer Dedicated Teacher Award, presented
in 2012 by the American College of Physicians
(Nebraska Chapter); several UNMC Internal
Medicine Top Teacher Awards, the most recent
in 2010; the 2008 Hirshmann Golden Apple Prize
(pre-clinical), awarded by the UNMC College of
Medicine Class of 2008, and a slew of others.

you don’t get that individualized attention – with
Dr. Moore, that’s definitely there.”
Ted Mikuls, MD, MSPH, cites Dr. Moore— “a
great rheumatologist with a foundation as a
great internist” —as a major influence, not only
on Dr. Mikuls, but on other senior faculty in the
department, as well.
“As a student, there was never any ambiguity
about expectations or feedback. As a student,
if you don’t know where you stand with Dr.
Moore, you probably need a hearing check,” Dr.
Mikuls said. “What has set him apart from other
instructors is his simultaneous respect for what
many think of as ‘old school’ values in medicine—
like the central role of the history and the art of
the physical exam—and how he has been able
to successfully blend this with new technologies
and other innovative ways to communicate with
students across the spectrum of medical school
training.”

A current fourth-year medical student, Marshall
Davis, says Dr. Moore is a superlative instructor.
“He spends a lot of extra time individually with the
students, especially in clinic,” Davis said. “We’d
sit down and go through the case, and he’ll
usually go through a few teaching points for each
patient. Sometimes, when you work in groups,
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Registry, research offer
insights into RA risk factors
Ted Mikuls, MD, MSPH, is spearheading two efforts
aimed at helping rheumatoid arthritis sufferers
Dr. Mikuls, Professor of Internal Medicine, is
spearheading two efforts that could make
a big difference for the millions of people
suffering with rheumatoid arthritis (RA): an
examination of a possible cause of RA and a
patient registry that continues to offer valuable
insights into RA risk factors and outcomes.
The question of whether periodontal disease
could be a cause of RA is the focus of
research being done by investigators in
the Division of Rheumatology at UNMC.
Led by Dr. Mikuls in collaboration with
VA hospitals in Omaha, Dallas, Salt Lake
City, and Washington D.C., the research
initiative has enrolled 617 arthritis
patients to take part in the study.
Several studies have shown statistical
correlations between severe gum disease
and RA. While correlation does not equate
to causation, UNMC researchers are
looking more closely at the issue.
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“We’re assessing the possible role of different
bacteria that live under the gums,” Dr.
Mikuls said. “Early research from our group
and others suggests that at least one
of these bacterial species causing gum
disease may trigger the early immunity
that characterizes rheumatoid arthritis.”
But research for its own sake is not
the point, Dr. Mikuls emphasizes. It is
only a step toward the real goal.
“Who cares if we can say there’s this
relationship?” Dr. Mikuls said. “That does
not get us anywhere. The ultimate goal is
to develop an intervention to treat or even
prevent rheumatoid arthritis in the first place.”
This may involve better management of the
bacteria that is present in a person’s gums or
more effective cleaning methods. While those
in the periodontal community are already
working to develop advances in this area, any
evidence linking RA to periodontal disease
(PD) might help direct these advances.

In addition to studying those who contract
RA, the study also looks at family members
of patients who develop antibodies for the
disease but don’t yet have the disease. This
is part of how the study seeks to understand
the early role of PD in the development
of autoimmunity that leads to RA.
One result the UNMC researchers hope to
achieve is a set of recommendations that
would allow people to take proactive steps
many years before they become susceptible
to RA, as well as insight that can be helpful to
those who are involved in periodontal care.
To address the aims of the study, an
international multidisciplinary research team
was gathered with extensive expertise in the
epidemiology and immunology of RA and
periodontitis and includes Dr. Jeffrey Payne
from the UNMC College of Dentistry. The
team’s access to important and highly unique
patient populations will allow for the first

From left to right: Alan Erickson, MD
and Ted Mikuls, MD, MSPH

comprehensive examination of the association
of PD and related bacterial infections with RA.
Dr. Mikuls also heads Veteran Affairs
Rheumatoid Arthritis registry (VARA), a
large national VA cohort of patients with RA,
among the largest such in North America.
The registry, created by Omaha VA and UNMC
researchers, contains information about military
veterans with RA. It may offer important
insight into RA risk factors and outcomes
in this highly unique patient population.
More than 2 million Americans suffer from
RA, and since females compose more than
two-thirds of those with the disease, most
research of the disease concerns females.
The veterans registry, VARA, stands to be an
important source of information in the study
of males with the disease, said Dr. Mikuls, who
oversees the registry at the Omaha division of the
VA Nebraska-Western Iowa Health Care System.

In RA, the immune system promotes
inflammation of the joints, leading to joint
deformity and functional disability.
Scientists know little about what causes
RA, but most believe both genetics and the
environment play a role in the disease.
The VARA registry allows researchers to examine
specific medical and biological information
about several thousand male RA sufferers to see
what genetic and environmental factors may
have played a role in the patients’ disease.
Leading RA scientists from around the nation,
including Dr. James O’Dell from UNMC,
have collaborated in research endeavors
capitalizing on data collected in VARA.
“The vast amount of detailed information available
to the database really makes this a critically
important research resource,” said Dr. O’Dell.

“The ultimate goal
is to develop an
intervention to treat
or even prevent
rheumatoid arthritis
in the first place.”
Ted Mikuls,
MD, MSPH

“While fewer men suffer from RA, that
doesn’t discount the fact that men compose
a significant portion of RA sufferers,” Dr.
Mikuls said. “Because the veteran population
is so overwhelmingly male, we are in a
special position to gather information
about men suffering from this disease.”
“Males account for almost 90 percent of the
roughly 2,128 veterans with information
in VARA—making it perhaps the nation’s
top source of information about male
RA sufferers,” Dr. Mikuls said.
Dr. Mikuls initiated VARA at the Omaha
VA in 2003. The database contains clinical
and biological information about the
patients. VARA includes a large biorepository
of DNA, serum, and patient plasma
collected at the time of enrollment.
At first, information came just from local
veterans with RA, but today VA medical centers
in Birmingham, Brooklyn, Dallas, Denver,
Iowa City, Jackson, Little Rock, Portland,
Philadelphia, Salt Lake City and Washington,
D.C., contribute information to the database.

9th annual VARA meeting hosted by UNMC
Division of Rheumatology in the Sorrell Center
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On the RISE
From left to right: Kaleb Michaud, PhD, and James O’Dell, MD

Kaleb Michaud, PhD,
is helping use
technology and
databases to better
serve RA patients.

Dr. Michaud isn’t afraid to think outside the
box when it comes to using technology to
better serve physicians and their patients.
He is working in collaboration with the
American College of Rheumatology (ACR)
on the Rheumatology Informatics System
for Effectiveness (RISE) Registry, launched
this year. The project’s long-term goal is to
have all of the rheumatology clinics in the
country enrolled and connected, providing a
pool of electronic medical records available
through the registry. UNMC Division of
Rheumatology is one of the early adopters.
For academic centers, this can be tricky, Dr.
Michaud said, because of the steps involved
with institutional review boards, contracts and
other considerations. “But in the end, the goal
would be that any rheumatologist can quickly
see how their patients or how their practice
is doing compared to everybody else in the
country,” he said. “So there’s that immediate
feedback and quality improvement aspect.”
Dr. Michaud is an expert when it comes to
databases. Since coming to the medical center in
2007, he has become involved with the Veteran
Affairs Rheumatoid Arthritis registry (VARA), the
RAIN Database as its Principal Investigator, and
as co-founder of the Arthritis Internet Registry
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(AIR). He also spends much of his time working
and collaborating with others as Co-director
of the National Data Bank for Rheumatic
Diseases (NDB), the world’s largest patientreported research databank for rheumatic
disorders, with more than 40,000 patients.
He is involved with many other projects and
research at UNMC: he has a lead role in the
Nebraska Arthritis Outcomes Research Center
(NAORC), is a recipient of a new investigator
award from the Arthritis Foundation to study the
cost-effectiveness in total joint replacement in
RA patients, received a NIH Challenge grant to
investigate the cost-effectiveness of biological
medications in RA treatment, and received an
investigator award from the Rheumatology
Research Foundation for assessing mortality in
RA—but the RISE Registry has been an ongoing
concern for Dr. Michaud. In fact, he was a
member of the original subcommittees and task
forces that helped create the first phase of the
project, the Rheumatology Clinical Registry. The
resource still exists, in fact, and is used to collect
data on many patients, but it doesn’t have any
direct tie-in with their electronic medical records.
The RISE Registry could be utilized to
address research questions, quantify which
treatments and drugs are working and how
well, and determined what rheumatologists

RISE Model
Research and
Discovery
Experimental
Learning from
Clinicians

Publication
Improved
Delivery of Patient
Care and Understanding
of Rheumatic
Disease

Implementation
of Quality Measures
in Clinical
Practice

Development of
Evidence-Based
Guidelines

“We need data to
back up whether
these measures
are useful...
That’s what RISE
is all about”
Kaleb Michaud, PhD

Development of
Quality Measures

are prescribing for certain conditions or
sub-conditions—any number of uses.
“There’s a multitude of questions that can
be asked,” Dr. Michaud said. “It has to start
with actually having clinics connect.”
Dr. Michaud estimates that about 20
clinics will be connected in 2014, with
adoption picking up quickly.
“You can easily see this ramping up
to 100 clinics in two years, and up to
500 in three to five years,” he said.
With a multitude of measures for “quality”
facing rheumatologists, from payers, national
insurance, and the Centers for Medicare
and Medicaid Services, the registry can help
define what these measures should be.
“Payers and other organizations are constantly
looking for new measures, especially measures
that might be helping to cut their costs,” he

said. “We need data to back up whether these
measures are useful. No one wins when you
have a rheumatologist who’s punished by an
insurance company or a payer—because they
see him as being too expensive or prescribing
too many expensive treatments—but he actually
has high-severity and more complicated
patients compared to somebody else. The
registry will provide data to back that up.”
With the registry, “we’re hoping to not have
to measure things twice,” Dr. Michaud
said. “Once it’s in the electronic medical
record, you can just take it directly from
there. That’s what RISE is all about.”
Yes, he admits, there is still work to do. But
in the end, RISE will improve patient health,
facilitate reporting requirements, and impact
research that will advance rheumatology.
It’s a project on the RISE—and Dr. Michaud
is one of the people who is helping lift it.
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RAIN man

James O’Dell, MD, with RA patient

Dr. James O’Dell and the Rheumatology and Arthritis Investigational Network
have led UNMC to an international profile in RA research.
As the leader of the Internal Medicine Residency
Training Program for more than 30 years,
Rheumatology Division Chief James O’Dell, MD,
has directed the training of more than 600
UNMC residents – researchers and physicians
who will shape treatment in internal medicine
and care of arthritis patients for years to come.
But Dr. O’Dell’s impact doesn’t stop
there. He also is considered a pioneer in
rheumatoid arthritis (RA) research.
Under Dr. O’Dell’s leadership, clinician-scientists
at UNMC have garnered an international
reputation in the treatment and research
of RA. Since 1989, faculty members have
repeatedly been responsible for breakthroughs
in RA treatment – most notably pioneering
the use of “Triple Therapy,” or combinations
of disease-modifying medications to treat RA.
Triple Therapy became popular in 1996 when
UNMC and researchers from the Rheumatology
and Arthritis Investigational Network (RAIN),
led by Dr. O’Dell, published a landmark study
in the New England Journal of Medicine.
RAIN has been critical to better understanding
RA treatment at the patient level. Directed by
Dr. O’Dell since its inception more than 20
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years ago, RAIN has become an internationally
respected and productive investigator-initiated
research network. The national consortium
includes 40 rheumatologists in six states
who participate in the design and enrollment
of patients in clinical protocols. In addition,
the first international site, in the Dominican
Republic, began participating in RAIN in 2013.
RAIN was among the first to report correlations
of treatment responses in RA with genes
regulating the immune system. RAIN studies have
also shown that a commonly used acne drug
and antibiotic, minocycline, provided significant
improvement for a subset of people with early RA.
Dr. O’Dell, who also served as President of the
American College of Rheumatology in 2012, was
the principal investigator for the Rheumatoid
Arthritis Comparison of Active Therapies (RACAT)
trial. Funded by the Veterans Administration
(VA), this $18 million study involved 16 VA sites,
eight sites in Canada and 12 sites in the RAIN
group, which included the Omaha VA Medical
Center and UNMC. For the first time, the RA
353-patient study combined a biorepository,
and strong prospective economic data with
a double-blind randomized clinical trial.

The cooperative blinded study found that the
use of less-expensive combination diseasemodifying anti-rheumatic drugs (DMARDs)
produced the same clinical benefits as a
much more-expensive biological treatment.
Results were published in the July 25, 2013
edition of the New England Journal of Medicine.
“Before the study, there was a general belief
that biologics have significantly more potency,
but this study has proven that not to be
the case in this patient population,” said Dr.
O’Dell. “This study shows when conventional
therapy is used before biologics, there should
be a significant cost-savings not only to
patients, but to the health care system.”
Dr. O’Dell said that one of the main reasons
for the study is that the cost of treating RA
has increased significantly and is now more
expensive per patient than diabetes, primarily
because of the use of biologic therapies.
“We are looking for the safest and most effective
medications,” Dr. O’Dell said. “The study shows
that patients who start on the conventional
combination therapy do just as well as people
who start on a much more expensive therapy.”
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two groups in ACR 20 and ACR 50 responses at
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Supplementary Appendix). A larger percentage of
participants in the etanercept–methotrexate group
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Radiographic Results

There was no significant difference between the
two groups in radiographic progression over
the course of 48 weeks (Table 2). Participants in
the triple-therapy group had a mean progression
of 0.54 Sharp score units, and participants in the
etanercept–methotrexate group had a mean progression of 0.29 Sharp score units (P = 0.43). Radiographic progression as assessed on the basis of
cumulative probability was not distinguishable between the two groups (Fig. S4 in the Supplementary Appendix).

DAS28 Mean Score

DAS28 Mean Score

A larger percentage of
University of British Columbia and CenWe conducted 5a 48-week, double-blind, noninferiority trial inSupplementary
which we randomlyAppendix).
for Health Evaluation and Outcome group
in5the tre
etanercept–methotrexate
assigned 353 participants with rheumatoid
arthritis
active disease despite
Triple
therapywho had participants
Sciences, Vancouver (A.H.A.), and Uni4
methotrexate therapy
to a triple regimen of disease-modifyinghad
antirheumatic
versity of Toronto
Mount Sinai
Hos-the difan ACRdrugs
704 response
at 24andweeks,
but
pital, Toronto (E.K.) — all in Canada; VA
(methotrexate, sulfasalazine, and hydroxychloroquine) or etanercept plus methoEtanercept–methotrexate
3
ference
was
atProgram
48 weeks.
Cooperative Studies
(CSP) Co- DAS28
trexate. Patients who did not have an improvement at 24 weeks
according
to anot
pre- maintained
3
ordinating Center, Boston (M.B., R.A.L.,
responses
favored
etanercept–methotrexate
specified threshold
were switched in a blinded fashion to the
other therapy.
The S.L.)
and thethroughout
Schools of Medicine (M.B.) ther- Functional Outcomes
2
Triple
and Public
Health
(R.A.L.),
Boston
Uniprimary outcome was improvement in the Disease Activity Score
counts
2 but
apyforat28-joint
24 weeks
did
not
differ
significantly
Both regimens resulted in clinically significant imTriple
with
to etanercept
versity,
Boston;
VAswitch
CSP Clinical
Research
(DAS28, with scores
ranging from 2 to 10 and higher scores indicating more dis1
Pharmacy
Coordinating
Center,
AlbuEtanercept
throughout
from
those
in
the
triple-therapy
group
at
48
weeks. provement in physical function (Table 2). All the
ease activity) at week 48.
1
querque, NM (S.R.W.); George E. Whalen
0

Results

Etanercept with switch to triple

0

24

48

participants, regardless of whether they continued

Radiographic
Results
Both groups had significant improvement over the course of
the first 24 weeks
the initial therapy or switched at 24 weeks, had a
Healthcare System, 48
0 and Palo Alto VA24
Week
Palo Alto (C.S.P.),
and Stanford between
Universi(P = 0.001 for the comparison with
baseline). A total of 27% ofThere
participants
was in
noeach
significant
difference
the significant improvement in the score on the health
ty School of Medicine,
WeekStanford (C.S.P.)
group
required
a
switch
in
treatment
at
24
weeks.
Participants
in
both
groups
who
No. Evaluated
— both in California. Address
reprint retwoandgroups
in radiographic
progression
over assessment questionnaire at the end of the trial
switched
(P<0.001),
the response
Triple
therapytherapies
178 had improvement
157 after switching
154
No. Evaluated
quests to Dr. O’Dell at the Veterans Affairs
the
course
of The
48
(Table
2). Participants
Nebraska–Western
Iowa
Health Care 115 in (Table S3A in the Supplementary Appendix).
after switching 175
did not differ significantly
between 155
the two groups
(P = 0.08).
Etanercept–
161
Triple
throughout
134weeks
113
4101 Woolworth
Ave., Omaha, 39
methotrexate
change between baseline and 48 weeks in the DAS28 was similar
intriple-therapy
the
groups44 System,
Triple
withtwo
switch
the
group
had
a44mean
progression
NE
68105, or
at james.o’dell@va.gov.
to etanercept
(−2.1 with triple therapy and −2.3 with etanercept and methotrexate,
P = 0.26); triple
ofEtanercept
0.54
Sharp
score
and117investigators
participants
in the Adverse Events and Discontinuation
131 *A units,
complete list of
in the 114
therapy
was
noninferior
to
etanercept
and
methotrexate,
since
the
95%
upper
conB Change in DAS28 According to Initial and Subsequent
throughout
Comparison
of Active
Theretanercept–methotrexate
had
a mean
pro- of Medication
fidence
limit of 0.41 for the difference in change in DAS28 was
below the margin CSP 551 RA:group
Treatment
Etanercept with
44 apies (RACAT) study
44 is provided in the 41
for noninferiority
of 0.6 (P = 0.002). There were no significant between-group
differ-Sharp
gression
0.29
score units
(P available
= 0.43).at Radio- Table 3 shows the adverse events and serious adSupplementary
Appendix,
7
switch toof
triple
ences in secondary outcomes, including radiographic progression, pain, and health- NEJM.org.
graphic
progression as assessed on the basis of verse events that were reported during the interrelated quality 6of life, or in major adverse events associated with
the medications.
was published on June 11,
Figure
1. Mean ScoresThis
onarticle
the DAS28.

James O’Dell, MD

cumulative probability
not distinguishable be- vention period and for 4 weeks after completion
2013, atwas
NEJM.org.
Panel A shows the mean scores on the Disease Activity
of the blinded intervention. Results are presented
according to the therapy that the participant was
receiving at the time of the event. After accounting for switching, 222 participants were exposed
to triple therapy, and 219 to etanercept–methoEtanercept
throughout
with rheumatoid arthritis
is excellent
if
provement
in
physical
function
(Table
2).
All
the
trexate therapy. The frequencies of adverse events
1
scores according to the therapies received durThe New England
Medicine
Etanercept with switch
triple Journal ofmean
therapy is started
Dr.byO’Dell
said.ontoJuly
participants,
regardless
ofpermission.
whether they
continued
were similar in the two groups (Table S4 in the
Downloadedearly,”
from nejm.org
JAMES ODELL
26, 2013. For personal
only. Noof
other
without
ing theusecourse
theuses
48-week
intervention
period.
Both
0
Copyright © 2013 Massachusetts Medical Society.
All rights therapy
reserved.
the
initial
orwho
switched
24 weeks,
groups
of participants
switchedat
therapies
at 24had a Supplementary Appendix). Gastrointestinal dis0
24
48
weeks (represented
by the top
theraDr. O’Dell also co-authored one Week
of the
significant
improvement
intwo
thecurves:
score triple
on the
health orders occurred more frequently with triple therpy to etanercept–methotrexate
andthe
etanercept–metholargest
clinical studies ever done to prove RA
assessment
questionnaire at
end of the trial apy, whereas infections and skin and subcutaneNo. Evaluated
trexate to triple therapy) had significant improvement
patients
start on
(Table
S3A in the Supplementary Appendix).
Triplecan
throughout
134 low cost monotherapy.
113
115
ous disorders occurred more frequently with
after the switch (P<0.001 for each), with no significant
Triple with switch 44
44
39
etanercept–methotrexate therapy. A total of 17
difference in the amount of improvement (P = 0.08). In
to etanercept
Adverse
Events
and Discontinuation
The study
was part131
of the Treatment
Etanercept
117 of Early 114
both panels,
I bars indicate
95% confidence intervals.
participants discontinued the intervention owing
throughout
of Medication
Aggressive
Rheumatoid
Arthritis (TEAR)
trial, 41
to an adverse event. Gastrointestinal disorders acEtanercept with
44
44
Table 3 shows the adverse events and serious adwhich received
great international interest. Of
switch to triple
312 started
engl j med
369;4
nejm.org july 25, 2013
verse events that were reportedn during
the
inter755 patients
in the 26-state study, 377
Figure 1. Mean Scores on the DAS28.
vention period and for 4 weeks
afterEngland
completion
on methotrexate
alone
and
28
percent
did not
The New
Journal of Medicine
Panel A shows the mean scores on the Disease Activity
of thefrom
blinded
intervention.
Results
nejm.org
by JAMES ODELL
on are
Julypresented
26, 2013. For personal use only. No other uses without permission.
needScore
to beforstepped
up to (DAS28,
anotherwith
treatment.
28-joint counts
scores rangingDownloaded
2013the
Massachusetts
Medical
according to theCopyright
therapy©that
participant
was Society. All rights reserved.
from
2 to 10treatments
and higher scores
more disease
Other
step-up
wereindicating
a “combination”
activity)
accordingoftomethotrexate,
the regimen to which
the particireceiving at the time of the event. After accountor “triple
therapy”
sulfasalazine
pants were randomly assigned at the beginning of the
ing for switching, 222 participants were exposed
and hydroxychloroquine,
or a biologic treatment
study. Triple therapy was noninferior to etanercept–
to triple therapy, and 219 to etanercept–methoof methotrexate
plus etanercept.
ThisBwas
very
methotrexate therapy
(P = 0.002). Panel
shows
the
trexate therapy. The frequencies of adverse events
mean
according
to theof
therapies
received dursignifi
cantscores
because
the cost
triple therapy
is
were similar in the two groups (Table S4 in the
ing
the
course
of
the
48-week
intervention
period.
Both
less than $1,000 compared to the etanercept
groups of participants who switched therapies at 24
Supplementary Appendix). Gastrointestinal distherapy
cost
of
over
$20,000
per
year.
Further,
weeks (represented by the top two curves: triple theraorders occurred more frequently with triple therthe potential
for rare but serious
has
py to etanercept–methotrexate
and toxicity
etanercept–methoapy, whereas infections and skin and subcutaneto triplewith
therapy)
significant
improvement
beentrexate
a concern
the had
biological
products.
ous disorders occurred more frequently with
after the switch (P<0.001 for each), with no significant
etanercept–methotrexate therapy. A total of 17
difference in the amount of improvement (P = 0.08). In
both panels, I bars indicate 95% confidence intervals.
participants discontinued the intervention owing
to an adverse event. Gastrointestinal disorders acStudy participant laughs with James O’Dell, MD, during a news conference at
UNMC. The patient participated in a study that showed a $1,000 rheumatoid
n engl j med 369;4 nejm.org july 25, 2013
arthritis treatment is as effective as a therapy that can cost over $20,000.
DAS28 Mean Score

Conclusions

tween
the two groups
(Fig.
S4 in the SupplemenN Engl J Med
2013;369:307-18.
With respect to5clinical benefit, triple therapy, with sulfasalazine
and hydroxychloScore for 28-joint counts
(DAS28, with scores ranging
“When I roquine
see patients,
I know I have
a lot of to etanercepttary
added to methotrexate,
was noninferior
plus methotrexate in DOI: 10.1056/NEJMoa1303006
Copyright
© 2013 indicating
Massachusetts Medical
Society.disease
4
from Appendix).
2 methotrexate
to 10 and higher
scores
more
patients
with
rheumatoid
arthritis
who
had
active
disease
despite
different treatment options to offer them.
activity)
according
to the regimen to which the particitherapy. (Funded
by
the
Cooperative
Studies
Program,
Department
of
Veterans
Affairs
3
Twenty Office
yearsofago
that
wasn’t
the case.
The CSP 551 RACAT
pants
were randomly
assigned at the beginning of the
Functional
Outcomes
Research
and
Development,
and others;
ClinicalTrials.gov
Triple
throughout
study.regimens
Triple therapy
was noninferior
to etanercept–
number,
NCT00405275.)
prognosis
for patients
newly
diagnosed
2
Both
resulted
in clinically
significant imTriple with
switch to etanercept
n engl j med 369;4 nejm.org july methotrexate
25, 2013
therapy (P = 0.002). Panel B shows307
the

312

The New England Journal of Medicine
Downloaded from nejm.org by JAMES ODELL on July 26, 2013. For personal use only. No other uses without permission.
Copyright © 2013 Massachusetts Medical Society. All rights reserved.

NEW FRONTIERS | Spring 2014

A top-tier
team player
Dr. Geoffrey Thiele’s crossdepartmental collaborations link
RA research with other disciplines.
Dr. Thiele knows the importance of sharing his lab for a greater
good. A career research scientist in the VA system, he directs the
Experimental Immunology Laboratories (EIL) at the Omaha VA and
UNMC, which have been existence since 1982. There, he leads efforts
to link rheumatoid arthritis (RA) research with other disciplines.
He currently helps to direct the efforts of two national VA bio-repositories,
including the Veteran Affairs Rheumatoid Arthritis (VARA) registry and
the more recently developed Crystal Registry (a large, multicenter gout
cohort from the VA). When specific studies are initiated, the EIL also runs
many of the assays to evaluate the immune parameters associated with
RA, such as Western blot, ELISA, immunohistochemistry and nephelometry.
Over the years, Dr. Thiele has collaborated with numerous
UNMC faculty, notably in four specific areas of research:
• To study alcoholic liver disease, with Lynell Klassen, MD, Chair of the
UNMC Department of Internal Medicine and a division faculty member
• To evaluate the relationship between periodontal
disease and RA with Ted Mikuls, MD, MSPH
• To investigate the latest outcomes in RA studies with James O’Dell, MD
• To study the effects of the immune system in artherosclerosis in
relation to RA with UNMC cardiologist Dan Anderson, MD, PhD

Geoffrey Thiele, PhD

Recently, Dr. Thiele worked with a team of researchers – including
cardiologist Dan Anderson, MD, PhD, on the discovery of a test that
determines whether a patient has a lethal form of coronary artery
disease by focusing on malondialdehyde-acetaldehyde (MAA), a molecule
that appears to indicate the presence of coronary artery disease.
Dr. Thiele’s work includes a growing number of cross-departmental
collaborations. Currently, Drs. Thiele and Mikuls have been
working with Dong Wang, PhD, in the UNMC College of
Pharmacy, studying nanoparticles as a new way of delivering antiinflammatory RA drugs at the site, rather than systemically.
Recently funded work with Kaihong Su, PhD, in the Department of
Pathology and Microbiology, investigates the role of anti-neutrophil
antibodies to initiated kidney damage in systemic lupus erythematous
(SLE) using a precision—cut kidney slice model as target tissue.
Additionally, studies with Laura Bilek, PhD, in the School of Allied
Health Professions, have focused on the effects of exercise on the
inflammatory markers in RA and resultant disease activity.
As a “seasoned scientist”, Dr. Thiele has played a key role in helping
newer faculty and students in the division develop their interests
in the rapidly expanding area of translational RA research.
“With the increased emphasis by the NIH and VA to perform research
with higher clinical significance and translational potential, the
studies performed by our group have generated the baseline data
from which other investigators will be able to start,” said Dr. Thiele.
“Because these samples have been well-characterized, an investigator
can immediately perform studies asking more specific questions,
allowing them to rapidly ask questions and get their answers.”
Dr. Thiele’s many collaborative efforts have paved the way for a
number of new investigations and studies at UNMC. His impact,
and his work at EIL, transcends a single discipline—and the
Division of Rheumatology is pleased to have him as a partner.

From left to right: Karen Easterling, BA, Michael Duryee, MS,
Anand Dusad, MD, and Bartlett Hamilton, III, BS
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Selected Faculty Publications Feb. 2013 – Feb. 2014
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Cannella, A.C., Kunkel G., Phibbs, C.S., Anis,
A.H., Leatherman S., Keystone E., CSP 551
RACAT Investigators. (2013). Therapies for
active rheumatoid arthritis after methotrexate
failure, N Engl J Med, 369(4) 307-18.
• Mikuls, T.R., Payne, J.B., Yu, F., Thiele, G.M.,
Reynolds, R.J., Cannon, G.W., Markt, J.,
McGowan, D., Kerr, G.S., Redman, R.S.,
Reimold, A., Griffiths G., Beatty, M., Gonzalez,
S., Bergman, D.A., Hamilton, B.C., Erickson,
A.R., Sokolove, J. Robinson, W., Walker, C.,
Chandad, F., O’Dell, J.R. (2014). Periodontitis
and porphyromonas gingivalis in Patients with
Rheumatoid Arthritis. Arthritis Rheum, In Press
• Dusad, A., Duryee, M.J., Shaw, A.T., Klassen,
L.W., Anderson, D.R., Wang, D., Ren, K.,
Gravallese, E.M., O’Dell, J.R., Mikuls, T.R.,
Thiele, G.M. (2014). Induction of bone loss
in DBA/1J mice immunized with citrullinated
autologous mouse type II collagen in the absence
of adjuvant. Immunol Res, 58 (1) 51-60.
• Quan, L., Zhang, Y., Crielaard, B.J., Dusad,
A., Lele, S.M., Rijcken, C.J., Metselaar, J.M.,
Kostkova, H., Etrych, T., Ulbrich, K., Kiessling,
F., Mikuls, T.R., Hennrick, W.E., Storm, G.,
Lammers, T., Wang, D. (2014). Nanomedicines for
inflammatory arthritis: head-to-head comparison
of glucocorticoid-containing polymers, micelles
and liposomes. ACS Nano, 8 (1), 458-66.

• Cannella, A.C., Kissen, E.Y., Torralba, K.D.,
Higgs, J.B., Kaeley, G.S. (2014). Evolution of
musculoskeletal ultrasound in the United
States: implementation and practice in
rheumatology. Arthritis Care Res, 66(1), 7-13.
• Michaud, K., Fehringer, E.V., Garvin, K.,
O’Dell, J.R., Mikuls, T.R. (2013). Rheumatoid
arthritis patients are not at increased
risk for 30-day cardiovascular events,
infections, or mortality after total joint
arthroplasty. Arthritis Res Ther, 15(6):R195.
• Carter, M.J., Mikuls, T.R., Nayak, S., Fehringer,
E.V., Michaud, K. (2013). Impact of total
shoulder arthroplasty on generic and shoulderspecific health-related quality-of-life measures:
a systematic literature review and metaanalysis. J Bone Joint Surg Am, 94(17):e127.
• Dusad, A., Thiele, G.M., Klassen, L.W., Gleason,
A.M., Bauer, C., Mikuls, T.R., Duryee, M.J., West,
W.W., Romberger, D.J., Poole, J.A. (2013). Organic
dust, lipopolysaccharide, and peptidoglycan
inhalant exposures result in bone/loss/disease.
Am J Respir Cell Mol Biol, 49(5), 829-36.
• Davis, M.L, Michaud, K., Sayles H., Conn,
D.L., Moreland, L.W., Bridges, S.L. Jr, Mikuls,
T.R. (2013). Associations of alcohol use with
radiographic disease progression in African
Americans with recent-onset rheumatoid
arthritis. J Rheumatol, 40(9), 1498-504.
• Young, K.A., Deane K.D., Derber, L.A., HughesAustin, J.M., Wagner, C.A., Sokolove, J., Weisman,
M.H., Buckner, J.H., Mikuls, T.R., O’Dell, J.R.,

Keating, R.M., Gregersen, P.K., Robinson, W.H.,
Holers, V.M., Norris, J.M. (2013). Relatives
without rheumatoid arthritis show reactivity
to anti-citrullinated protein/peptide antibodies
that are associated with arthritis-related
traits: studies of the etiology of rheumatoid
arthritis. Arthritis Rheum, 65(8), 1995-2004.
• O’Dell, J.R., Curtis, J.R., Mikuls, T.R., Cofield,
S.S., Bridges, S.L. Jr, Ranganath, V.K., Cofield,
S.S. (2013). Validation of the methotrexatefirst strategy in patients with early, poorprognosis rheumatoid arthritis: results
from a two-year randomized, double-blind
trial. Arthritis Rheum, 65(8), 1985-94.
• Anderson, D.R., Poterucha, J.T., Mikuls, T.R.,
Duryee, M.J., Garvin R.P., Klassen, L.W., Shurmur,
S.W., Thiele, G.M. (2013). Relationship between
air pollution and positivity of RA-related
autoantibodies in individuals with established RA:
a report on SERA. Ann Rheum Dis, 72(12), 2002-5.
• Garg, R., Sayles, H.R., Yu, F., Michaud, K.,
Singh, J., Saag, K.G., Mikuls, T.R. (2013).
Gout-related health care utilization in US
emergency departments, 2006 through
2008. Arthritis Care Res, 65(4), 571-7.
• Mikuls, T.R., Padala, P.R., Sayles, H.R., Yu, F.,
Michaud, K., Caplan, L., Kerr, G.S., Reimold, A.,
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of posttraumatic stress disorder and disease
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arthritis. Arthrits Care Res. 65(2), 227-34.

Research Awards
Mike Duryee, MS,
Research Coordinator,
Division of
Rheumatology, received
the first Daughton
Award for a non-faculty
employee whose
professional activities
such as teaching,
publications or scholarly research exceed what is
normally expected of individuals in the position. The
award was named for David Daughton, who had an
exemplary career in the area of smoking cessation
research and education in the Department.

Marshall Davis, M4
received a Student
Research Award for
his initiative and
exemplary work on his
research project. Davis’
work resulted in two
national presentations.

Bryant England, a
current second year
internal medicine
resident at UNMC,
was recently awarded
a prestigious
Resident Research
Preceptorship Award
from the Rheumatology
Research Foundation. The project, mentored by
Dr. Ted Mikuls in the Division of Rheumatology,
will examine the role of both traditional and
novel risk factors in predicting cardiovascular
mortality in patients with rheumatoid arthritis.

check out the
Amazon bookstore
to purchase a copy!
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